Phospho-ERK1 (T202/Y204) ELISA DYC1825-2 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemPhospho-ERK1 (T202/Y204) ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $495.00Supplier Page View Company Product Page
Catalog NumberDYC1825-2
NCBI Full Gene Namemitogen-activated protein kinase 3
NCBI Gene AliasesERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1, P44MAPK, PRKM3, p44-ERK1, p44-MAPK
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
Assay Time4 hours 40 minutes (after plate preparation)
Detection TargetERK1
ReactivityHuman, Mouse, Rat
Detection Range125.00 - 8000 pg/mL
ApplicationsELISA
Quantity1 Kit (for 2 Plates) (also 1 Kit (for 5 Plates), 1 Pack (for 15 Plates))

Specifications/Features

Available conjugates: Sizes Available: 1 Kit (for 2 Plates) (also 1 Kit (for 5 Plates), 1 Pack (for 15 Plates))

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) A novel ruthenium complex with 5-fluorouracil suppresses colorectal cancer stem cells by inhibiting Akt/mTOR signalingCell Death DiscovDecember 16, 2023Valdenizia R. Silva, Luciano de S. Santos, Maria V. L. de Castro, Rosane B. Dias, Ludmila de F. Valverde, Clarissa A. G. Rocha, Milena B. P. Soares, Claudio A. Quadros, Rodrigo S. Correa, Alzir A. Batista, et al.number #DYC2236-2), p38α (pT180/Y182) (catalog number #DYC869B-2) and ERK1 (pT202/Y204) (catalog number #DYC1825-2) were measured in cell lysates using sandwich ELISA kits (all from R&D Systems, Inc. Minneapolis, MN,

(2) Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling PathwayInternational journal of molecular sciencesMay 25, 2022Ebrahim N, Al Saihati HA, Mostafa O, Hassouna A, Abdulsamea S, Abd El Aziz M El Gebaly E, Abo-Rayah NH, Sabry D, El-Sherbiny M, Madboly AG, et al.(PEL-JNK-T183, RayBiotech, GA, USA), ERK (MBS034880, MyBiosource, San Diego, CA, USA), Phospho-ERK (DYC1825-2, R&D Systems, Minneapolis, MN, USA), and Phospho-STAT3/STAT3 (ab176666, Abcam, MA, USA) using the ELISA

(3) Ruthenium(II) complexes with 6-methyl-2-thiouracil selectively reduce cell proliferation, cause DNA double-strand break and trigger caspase-mediated apoptosis through JNK/p38 pathways in human acute promyelocytic leukemia cellsScientific ReportsDecember 1, 2019Larissa M. Bomfim, Fênix A. de Araujo, Rosane B. Dias, Caroline B. S. Sales, Clarissa A. Gurgel Rocha, Rodrigo S. Correa, Milena B. P. Soares, Alzir A. Batista, Daniel P. BezerraDYC2288-2), JNK2 (T183/Y185) (ID DYC2236-2), p38α (T180/Y182) (DYC869B-2) and ERK1 (T202/Y204) (ID DYC1825-2) expressions were quantified in cell lysates using sandwich ELISA kits (all from R&D Systems, Inc. Minneapolis,

(4) Stand-Sit Microchip for High-Throughput, Multiplexed Analysis of Single Cancer CellsScientific reportsSeptember 1, 2016Ramirez L, Herschkowitz JI, Wang J.

(5) Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activationAtherosclerosisSeptember 1, 2014Clancy P, Koblar SA, Golledge J.

(6) The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patientsThe Journal of biological chemistryJuly 26, 2013Sunahori K, Nagpal K, Hedrich CM, Mizui M, Fitzgerald LM, Tsokos GC.

(7) Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonistCancer researchSeptember 1, 2012Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, Klammer M, Tebbe A.

(8) Microarray-based kinetic colorimetric detection for quantitative multiplex protein phosphorylation analysisProteomicsMay 1, 2011Holenya P, Kitanovic I, Heigwer F, Wölfl S.

(9) Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expressionBMC cancerFebruary 14, 2011Zhang Y, Gonzalez RM, Zangar RC.

(10) Real-time monitoring of cisplatin-induced cell deathPloS oneJanuary 1, 2011Alborzinia H, Can S, Holenya P, Scholl C, Lederer E, Kitanovic I, Wölfl S.

(11) Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cellsJournal of immunology (Baltimore, Md. : 1950)March 15, 2008Lau AW, Biester S, Cornall RJ, Forrester JV.

(12) Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor modelsMolecular cancer therapeuticsFebruary 1, 2008Wang S, Guo P, Wang X, Zhou Q, Gallo JM.

(13) In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and toleranceBritish journal of pharmacologyDecember 1, 2007Aguila B, Coulbault L, Boulouard M, Léveillé F, Davis A, Tóth G, Borsodi A, Balboni G, Salvadori S, Jauzac P, et al.

(14) Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migrationBloodJuly 1, 2007Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, et al.